News

uMotif Announces Andrea Valente is Chief Executive Officer
Press Release

June 1, 2026

uMotif Announces Andrea Valente is Chief Executive Officer

Read More
18 months of FDA’s Core Patient-Reported Outcomes in Cancer Clinical Trials Guidance – have we seen its impact? 
Blog

May 26, 2026

18 months of FDA’s Core Patient-Reported Outcomes in Cancer Clinical Trials Guidance – have we seen its impact? 

Read More
eCOA Platform Innovator uMotif Launches Scientific Consulting Services
Press Release

May 13, 2026

eCOA Platform Innovator uMotif Launches Scientific Consulting Services

Read More
Managing eCOA Data: Best Practices Across the Clinical Trial Lifecycle
Article

May 5, 2026

Managing eCOA Data: Best Practices Across the Clinical Trial Lifecycle

Read More
uMotif Appoints James Thatcher Chief Commercial Officer
Press Release

May 5, 2026

uMotif Appoints James Thatcher Chief Commercial Officer

Read More
uMotif CEO Steve Rosenberg, Visionary Clinical Trial Technology Leader, to Retire; Industry Veteran and uMotif COO Andrea Valente to Take on Top Role 
Press Release

April 23, 2026

uMotif CEO Steve Rosenberg, Visionary Clinical Trial Technology Leader, to Retire; Industry Veteran and uMotif COO Andrea Valente to Take on Top Role 

Read More
uMotif Posts Strong Growth, Earns Market Accolades for eCOA Platform, Demonstrates Continued Clinical Trial Industry Leadership in 2025
Press Release

January 29, 2026

uMotif Posts Strong Growth, Earns Market Accolades for eCOA Platform, Demonstrates Continued Clinical Trial Industry Leadership in 2025

Read More
The imperative for patient centricity in clinical research in the Age of AI 
Article

January 15, 2026

The imperative for patient centricity in clinical research in the Age of AI 

Read More
The Challenges of Buying Blind: Why Providing the Clinical Outcome Assessment Measure Prior to License Execution Would Significantly Benefit Clinical Trial Set-Up 
Article

January 13, 2026

The Challenges of Buying Blind: Why Providing the Clinical Outcome Assessment Measure Prior to License Execution Would Significantly Benefit Clinical Trial Set-Up 

Read More